The Impact of Inherited Retinal Diseases in the Republic of Ireland (ROI) and the United Kingdom (UK) from a Cost-of-Illness Perspective
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
To date, there has been a global lack of data regarding the prevalence of conditions falling under the Inherited Retinal Diseases (IRD) classification, the impact on the individuals and families affected, and the cost burden to economies. The absence of an international patient registry, and equitable access to genetic testing, compounds this matter. The resulting incomplete knowledge of the impact of IRDs hinders the development and commissioning of clinical services, provision of treatments, and planning and implementation of clinical trials. Thus, there is a need for stronger evidence to support value for money to regulatory bodies for treatments approved, and progressing through clinical trials. To ensure a strategic approach to future research and service provision, it is necessary to learn more about the IRD landscape. This review highlights two recent cost-of-illness reports on the socio-economic impact of 10 IRDs in the Republic of Ireland (ROI) and the United Kingdom (UK), which demonstrate the comprehensive impact of IRDs on individuals affected, their families, friends and society. Total costs attributable to IRDs in the ROI were estimated to be £42.6 million in 2019, comprising economic (£28.8 million) and wellbeing costs (£13.8 million). Wellbeing costs were estimated using the World Health Organization (WHO) burden of disease methodology, a non-financial approach, where pain, suffering and premature mortality are measured in terms of disability-adjusted-life-years (DALYs). In the UK, wellbeing costs attributable to IRDs were £196.1 million, and economic costs were £327.2 million amounting to £523.3 million total costs in 2019. Accounting for over one-third of total costs, the wellbeing burden of persons affected by IRDs should be emphasized and factored into reimbursement processes for therapies and care pathways. This targeted review presents the most current and relevant data on IRD prevalence in the ROI and the UK, and the impacts (financial and non-financial) of IRDs in terms of diagnosis, wellbeing, employment, formal and informal care, health system costs, deadweight losses and issues surrounding payers and reimbursement. This review demonstrates IRD patients and their families have common issues including, the need for timely equitable access to genetic testing and counselling, equality in accessing employment, and a revision of the assessment process for reimbursement of therapies currently focused on the cost-of-illness to the healthcare system. This review reveals that IRD patients do not frequently engage the healthcare system and as such suggests a cost-of-illness model from a societal perspective may be a better format.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“other international studies suggested that 81% to 90% of the costs associated with IRDs are indirect and intangible [80–84].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [84]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Health at a Glance 2017: OECD Indicators
OECD (2017) · Health at a Glance · doi:10.1787/health_glance-2017-en · Cited by 768
Minimal Clinically Important Difference: Defining What Really Matters to Patients
McGlothlin, A. E., & Lewis, R. J. (2014) · JAMA · doi:10.1001/jama.2014.13128 · Cited by 703
A 2020 vision of patient-centered primary care
Davis, K., Schoenbaum, S. C., & Audet, A.-M. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0178.x · Cited by 683
Richter, T., Nestler-Parr, S., Babela, R., Khan, Z. M., Tesoro, T., Molsen, E., & Hughes, D. A. (2015) · Value in Health · doi:10.1016/j.jval.2015.05.008 · Cited by 590
Maguire, A. M., Russell, S., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., Marshall, K. A., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.06.017 · Cited by 409 · cited 1×
“16 Typically, such trials and treatments require that a causative variant has been identi fi ed in order to participate.”
Cost of stroke in the United Kingdom
Saka, O., McGuire, A., & Wolfe, C. (2008) · Age and Ageing · doi:10.1093/ageing/afn281 · Cited by 337
Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps
Duncan, J. L., Pierce, E. A., Laster, A. M., Daiger, S. P., Birch, D. G., Ash, J. D., Iannaccone, A., Flannery, J. G., Sahel, J. A., Zack, D. J., et al. (2018) · Translational Vision Science & Technology · doi:10.1167/tvst.7.4.6 · Cited by 257
Cost of cardiovascular diseases in the United Kingdom
Luengo-Fernández, R., Leal, J., Gray, A., Petersen, S., & Rayner, M. (2006) · Heart · doi:10.1136/hrt.2005.072173 · Cited by 203
A shorter working week for everyone: How much paid work is needed for mental health and well-being?
Kamerāde, D., Wang, S., Burchell, B. J., Balderson, U., & Coutts, A. P. (2019) · Social Science & Medicine · doi:10.1016/j.socscimed.2019.06.006 · Cited by 176
Visual Function, Social Position, and Health and Life Chances: The UK Biobank Study
Cumberland, P. M., Rahi, J. S., & for the UK Biobank Eye and Vision Consortium (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.1778 · Cited by 160
Research works printed but not linked: 6
- Sergouniotis, 2019, Ophthalmologica, 5, 1
- Stuart, 2018, Eye Net Mag, 2018, 43
- Zhao, 2019, J Ophthalmol, 21, 8524607
- 2014, Registries for Evaluating Patient Outcomes: A User’s Guide. Patient Registries
- Zhang, 2019, Mol Genet Genomic Med, 7, e916, 10.1002/mgg3.v7.9 · DOI
- 2017, Juggling Care and Daily Life: The Balancing Act of the Rare Disease Community
Cited by
Georgiou, M., Robson, A. G., Fujinami, K., de Guimarães, T. A. C., Fujinami‐Yokokawa, Y., Varela, M. D., Pontikos, N., Kalitzeos, A. A., Mahroo, O. A., Webster, A. R., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101244 · Cited by 137
Self-citationVariant reclassification and clinical implications
Walsh, N., Cooper, A., Dockery, A., & O’Byrne, J. J. (2024) · Journal of Medical Genetics · doi:10.1136/jmg-2023-109488 · Cited by 100
The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67
“With one exception they are untreatable, and therefore have devastating personal, social and economic costs (Galvin et al., 2020).”
BackgroundOptogenetics for visual restoration: From proof of principle to translational challenges
Lindner, M., Gilhooley, M. J., Hughes, S., & Hankins, M. W. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101089 · Cited by 65
Valero-Velló, M., Peris‐Martínez, C., García‐Medina, J. J., Sanz-Gonzalez, S. M., Ramirez, A. I., Fernández‐Albarral, J. A., Galarreta, D., Zanón‐Moreno, V., Casaroli-Marano, R. P., & Pinazo-Duran, M. D. (2021) · Foods · doi:10.3390/foods10061231 · Cited by 73
Leroy, B. P., Birch, D. G., Duncan, J. L., Lam, B. L., Koenekoop, R. K., Porto, F. B. O., Russell, S. R., & Girach, A. (2021) · Retina · doi:10.1097/iae.0000000000003133 · Cited by 71
Valuing the “Burden” and Impact of Rare Diseases: A Scoping Review
Delaye, J., Cacciatore, P., & Kole, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.914338 · Cited by 73
Findings from a Genotyping Study of over 1000 People with Inherited Retinal Disorders in Ireland
Whelan, L., Dockery, A., Wynne, N., Zhu, J., Stephenson, K. A. J., Silvestri, G., Turner, J., O’Byrne, J. J., Carrigan, M., Humphries, P., et al. (2020) · Genes · doi:10.3390/genes11010105 · Cited by 62
Next-Generation Sequencing Applications for Inherited Retinal Diseases
Dockery, A., Whelan, L., Humphries, P., & Farrar, G. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115684 · Cited by 65
Gene-Based Therapeutics for Inherited Retinal Diseases
Fenner, B. J., Tan, T., Barathi, V. A., Tun, S. B. B., Yeo, S. W., Tsai, A. S. H., Lee, S. Y., Cheung, C. M. G., Chan, C. M., Mehta, J. S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.794805 · Cited by 68
Michaelides, M., Hirji, N., Wong, S. C., Besirli, C. G., Zaman, S., Kumaran, N., Georgiadis, A., Smith, A. J., Ripamonti, C., Gottlob, I., et al. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2023.05.009 · Cited by 54
Self-citationProteostasis in aging-associated ocular disease
Weinberg, J., Gaur, M., Swaroop, A., & Taylor, A. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101157 · Cited by 60
Fujinami‐Yokokawa, Y., Ninomiya, H., Liu, X., Yang, L., Pontikos, N., Yoshitake, K., Iwata, T., Sato, Y., Hashimoto, T., Tsunoda, K., et al. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-318544 · Cited by 52
Retinal imaging in inherited retinal diseases
Georgiou, M., Fujinami, K., & Michaelides, M. (2020) · Annals of Eye Science · doi:10.21037/aes-20-81 · Cited by 52
Self-citationSallum, J. M. F., Kaur, V. P., Shaikh, J., Banhazi, J., Spera, C., Aouadj, C., Viriato, D., & Fischer, M. D. (2022) · Advances in Therapy · doi:10.1007/s12325-021-02036-7 · Cited by 49
Blindness and visual impairment in Central Europe
Glatz, M., Riedl, R., Glatz, W., Schneider, M. R., Wedrich, A., Bolz, M., & Strauss, R. W. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261897 · Cited by 49
Structural evaluation in inherited retinal diseases
Varela, M. D., Esener, B., Hashem, S. A., de Guimarães, T. A. C., Georgiou, M., & Michaelides, M. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-319228 · Cited by 43
Self-citationStem cell therapy for inherited retinal diseases: a systematic review and meta-analysis
Chen, X., Xu, N., Li, J., Zhao, M., & Huang, L. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03526-x · Cited by 46
RNA-based therapies in inherited retinal diseases
Girach, A., Audo, I. S., Birch, D. G., Huckfeldt, R. M., Lam, B. L., Leroy, B. P., Michaelides, M., Russell, S. R., Sallum, J. M. F., Štingl, K., et al. (2022) · Therapeutic Advances in Ophthalmology · doi:10.1177/25158414221134602 · Cited by 48
Self-citationNguyen, Q., Woof, W. A., Kabiri, N., Sen, S., Varela, M. D., de Guimarães, T. A. C., Shah, M., Sumodhee, D., Moghul, I., Al‐Khuzaei, S., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-071043 · Cited by 36
Self-citationNext-generation phenotyping of inherited retinal diseases from multimodal imaging with Eye2Gene
Pontikos, N., Woof, W. A., Lin, S., Ghoshal, B., Mendes, B. S., Veturi, Y. A., Nguyen, Q., Javanmardi, B., Georgiou, M., Hustinx, A., et al. (2025) · Nature Machine Intelligence · doi:10.1038/s42256-025-01040-8 · Cited by 49
Self-citationWatson, A., & Lako, M. (2022) · Journal of Anatomy · doi:10.1111/joa.13768 · Cited by 35
Varela, M. D., Bellingham, J., Motta, F. L., Jurkutė, N., Ellingford, J. M., Quinodoz, M., Oprych, K., Niblock, M., Janeschitz‐Kriegl, L., Kamińska, K., et al. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac227 · Cited by 32
Self-citationCost-of-illness studies of inherited retinal diseases: a systematic review
Ng, Q. X., Ong, C., Yaow, C. Y. L., Chan, H. W., Thumboo, J., Wang, Y., & Koh, G. C. H. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03099-9 · Cited by 27
“The need for lifelong monitoring and intervention further adds to the healthcare expenses [6, 7].”
BackgroundMethodInfluentialBritten‐Jones, A. C., O’Hare, F., Edwards, T. L., & Ayton, L. N. (2022) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14110 · Cited by 26
Emerging Therapeutic Approaches and Genetic Insights in Stargardt Disease: A Comprehensive Review
Ghenciu, L. A., Hațegan, O. A., Stoicescu, E. R., Iacob, R., & Șișu, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168859 · Cited by 29
Liu, F., Qin, Y., Huang, Y., Gao, P., Li, J., Yu, S., Jia, D., Chen, X. '., Lv, Y., Tu, J., et al. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1009841 · Cited by 27
Schofield, D., Kraindler, J., Tan, O., Shrestha, R. N., West, S., Hart, N., Tan, L., Ma, A., Grigg, J. R., & Jamieson, R. V. (2023) · Medical Journal of Australia · doi:10.5694/mja2.51997 · Cited by 22
The Current State of Genetic Testing Platforms for Inherited Retinal Diseases
Mustafi, D., Hisama, F. M., Huey, J., & Chao, J. R. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.03.011 · Cited by 22
Stephenson, K. A. J., Zhu, J., Wynne, N., Dockery, A., Cairns, R. M., Duignan, E. S., Whelan, L., Malone, C. P., Dempsey, H., Collins, K., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01841-1 · Cited by 21
Self-citationStargardt macular dystrophy and therapeutic approaches
Fujinami, K., Waheed, N. K., Laich, Y., Yang, P. G., Fujinami‐Yokokawa, Y., Higgins, J. J., Lu, J. T., Curtiss, D., Clary, C. M., & Michaelides, M. (2023) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-323071 · Cited by 38
Self-citationRPGR-Related Retinopathy: Clinical Features, Molecular Genetics, and Gene Replacement Therapy
Hashem, S. A., Georgiou, M., Ali, R. R., & Michaelides, M. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041280 · Cited by 19
Self-citationTan, T., Chan, H. W., Singh, M. S., Wong, T. Y., Pulido, J. S., Michaelides, M., Sohn, E. H., & Ting, D. S. W. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-319365 · Cited by 17
Self-citationPontikos, N., Woof, W. A., Veturi, Y. A., Javanmardi, B., Ibarra-Arellano, M. A., Hustinx, A., Moghul, I., Liu, Y., Pfau, K., Georgiou, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2110140/v1 · Cited by 18
Self-citationKessel, L., Kjellberg, J., Nissen, K. R., Rasmussen, A., & la Cour, M. (2022) · Ophthalmic Genetics · doi:10.1080/13816810.2022.2089359 · Cited by 18
Chay, J., Tang, R. W. C., Tan, T.-E., Chan, C. M., Mathur, R., Lee, B. J. H., Chan, H. H., Sim, S. S. K. P., Farooqui, S., Teo, K. Y. C., et al. (2023) · Eye · doi:10.1038/s41433-023-02624-7 · Cited by 15
Lorenz, B., Tavares, J. F., van den Born, L. I., Marques, J. P., Scholl, H. P. N., & the EVICR.net Group (2021) · Ophthalmic Research · doi:10.1159/000514540 · Cited by 15
Watanabe, K., Aouadj, C., Hiratsuka, Y., Yamamoto, S., & Murakami, A. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02446-9 · Cited by 13
“…been reported in other countries, including the Republic of Ireland and the UK [40,680 USD/person (27,988 pounds ster-ling/person) and 36,541 USD/person (25,140 pounds sterling/person), respectively; 0.688 pounds sterling was converted to 1 USD to calculate the USD equivalent of each cost] [33].”
InfluentialGene Therapy for Achromatopsia
Baxter, M. F., & Borchert, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179739 · Cited by 14
Gene Therapy in X-linked Retinitis Pigmentosa Due to Defects in RPGR
Georgiou, M., Hashem, S. A., Varela, M. D., & Michaelides, M. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000384 · Cited by 13
Self-citationPaudel, N., Daly, A., Waters, F., & Stratieva, P. (2024) · Ophthalmic Research · doi:10.1159/000537818 · Cited by 11
Self-citationWong, W. M., Tham, Y. C., Ayton, L. N., Britten‐Jones, A. C., Edwards, T. L., Grigg, J., Simunovic, M. P., Chen, F. K., Jin, Z., Shen, R., et al. (2024) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2024.100098 · Cited by 13
Self-citationGene editing technology: Towards precision medicine in inherited retinal diseases
Ballios, B. G., Pierce, E. A., & Huckfeldt, R. M. (2021) · Seminars in Ophthalmology · doi:10.1080/08820538.2021.1887903 · Cited by 13
Usher Syndrome on the Island of Ireland: A Genotype-Phenotype Review
Stephenson, K. A. J., Whelan, L., Zhu, J., Dockery, A., Wynne, N., Cairns, R. M., Kirk, C. W., Turner, J., Duignan, E. S., O’Byrne, J. J., et al. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.10.23 · Cited by 13
Zhu, J., Stephenson, K. A. J., Dockery, A., Turner, J., O’Byrne, J. J., Fitzsimon, S., Farrar, G. J., Flitcroft, I., & Keegan, D. (2022) · Genes · doi:10.3390/genes13040615 · Cited by 11
Redgrave, S., & McNeill, A. (2022) · Journal of Genetic Counseling · doi:10.1002/jgc4.1601 · Cited by 12
Kessel, L., Kjellberg, J., Ibsen, R., Rasmussen, A., Nissen, K. R., & la Cour, M. (2022) · BMC Ophthalmology · doi:10.1186/s12886-022-02708-0 · Cited by 8
Current management of inherited retinal degenerations in Portugal (IRD-PT survey)
Marques, J. P., Ferreira, N., Moreno, N., Marta, A. A., Vaz-Pereira, S., Estrela‐Silva, S., Costa, J. F., Cardoso, A. R., Neves, P., Duarte, L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-72589-4 · Cited by 10
Parmeggiani, F., Weber, M., Brémond‐Gignac, D., Daly, A., Denee, T. R., Lahaye, M., Lotery, A. J., Paudel, N., Ritter, M., Rodríguez-de-la-Rúa-Franch, E., et al. (2025) · Eye · doi:10.1038/s41433-024-03546-8 · Cited by 11
Self-citationInteraction between native and prosthetic visual responses in optogenetic visual restoration
Carpentiero, E., Hughes, S., Rodgers, J., Xhaferri, N., Biswas, S., Gilhooley, M. J., Hankins, M. W., & Lindner, M. (2025) · JCI Insight · doi:10.1172/jci.insight.190785 · Cited by 7
Thirunavukarasu, A. J., Raji, S., & Cehajic‐Kapetanovic, J. (2025) · Gene Therapy · doi:10.1038/s41434-025-00552-7 · Cited by 10
Rationale and protocol paper for the Asia Pacific Network for inherited eye diseases
Wong, W., Tham, Y. C., Simunovic, M. P., Chen, F. K., Luu, C. D., Chen, H., Jin, Z., Shen, R., Li, S., Sui, R., et al. (2024) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2023.100030 · Cited by 8
Self-citationGilbert, R. M., Sumodhee, D., Pontikos, N., Hollyhead, C., Patrick, A., Scarles, S., Smissen, S. V. D., Young, R., Nettleton, N., Webster, A. R., et al. (2021) · JMIR Formative Research · doi:10.2196/21341 · Cited by 8
Lorenz, B., Tavares, J., van den Born, L. I., Marques, J. P., Pilotto, E., Štingl, K., Issa, P. C., Leroux, D., Dollfus, H., & Scholl, H. P. N. (2023) · Ophthalmic Research · doi:10.1159/000529777 · Cited by 8
Patient-Reported Social Impact of Molecularly Confirmed Retinitis Pigmentosa
Zehe-Lindau, N., Lindau, B., Stöhr, H., Weber, B. H. F., Spital, G., & Kellner, U. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093229 · Cited by 7
McGuinness, M. B., Britten‐Jones, A. C., Ayton, L. N., Finger, R. P., Chen, F. K., Grigg, J., & Mack, H. G. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.2.14 · Cited by 8
Increased H3K27 trimethylation contributes to cone survival in a mouse model of cone dystrophy
Miller, A. L., Fuller-Carter, P. I., Masarini, K., Samardzija, M., Carter, K. W., Rashwan, R., Lim, X. R., Brunet, A. A., Chopra, A., Ram, R., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04436-6 · Cited by 7
Seah, I. Y. J., Goh, D., Banerjee, A., & Su, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1328474 · Cited by 10
Hitch, J., Denee, T. R., Brassel, S., Lee, J., Michaelides, M., Petersen, J. S., Alulis, S., & Steuten, L. (2024) · Value in Health · doi:10.1016/j.jval.2024.08.009 · Cited by 6
Self-citationOh, R., Woo, S. J., & Joo, K. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06309-5 · Cited by 6
Bušányová, B., Vajter, M., Kelifová, S., Lišková, P., Miková, H., Breciková, K., Zigmond, J., Rogalewicz, V., Tichopád, A., Višňanský, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32296 · Cited by 6
The Landscape of Genomic Services for Inherited Retinal Degenerations (IRDs) Across Europe
Paudel, N., Daly, A., Moran, E. M., & Stratieva, P. (2024) · Clinical ophthalmology · doi:10.2147/opth.s465930 · Cited by 6
Self-citationDaniele, E., Bosio, L., Hussain, N. A., Ferrari, B., Ferrari, S., Barbaro, V., McArdle, B., Rassu, N., Mura, M., Parmeggiani, F., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281404 · Cited by 6
Progressive Cone-Rod Dystrophy and RPE Dysfunction in Mitfmi/+ Mice
García‐Llorca, A., Ólafsson, K. H., Sigurdsson, A. T., & Eysteinsson, Þ. (2023) · Genes · doi:10.3390/genes14071458 · Cited by 6
The role of epigenetic changes in the pathology and treatment of inherited retinal diseases
Miller, A. L., James, R. E., Harvey, A. R., Trifunović, D., & Carvalho, L. S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1224078 · Cited by 7
Pungor, K., Lee, J., Denee, T. R., Kambarov, Y., Nissinen, R., Ampeh, K., Pellegrini, M., & Parmeggiani, F. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02935-5 · Cited by 5
Repo, P. E., Järvinen, R., Sankila, E., Paavo, M., Ellonen, P., Kivelä, T., & Turunen, J. A. (2020) · Clinical Genetics · doi:10.1111/cge.13847 · Cited by 5
Progress of iPSC-derived retinal organoids in the study of inherited retinal diseases
Liu, B., Liu, Y., Zhang, H., Huang, J., & Liu, G. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-04059-7 · Cited by 5
The socioeconomic epidemiology of inherited retinal diseases in Portugal
Marta, A. A., Marques, J. P., Santos, C., Coutinho-Santos, L., Vaz-Pereira, S., Costa, J. F., Arede, P., Félix, R., Geada, S., Gouveia, N. M. S., et al. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03161-6 · Cited by 5
Yang, T., Wang, W., Xie, L., Chen, S., Ye, X., Shen, S., Chen, H., Qi, L., Cui, Z., Xiong, W., et al. (2024) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2024.110181 · Cited by 4
Genes and Gene Therapy in Inherited Retinal Disease
Shughoury, A., Ciulla, T. A., Bakall, B., Pennesi, M. E., Kiss, S., & Cunningham, E. T. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000377 · Cited by 4
Diagnostic Challenges in ABCA4-Associated Retinal Degeneration: One Gene, Many Phenotypes
Tan, T., Tang, R. W. C., Chan, C. M., Mathur, R. S., & Fenner, B. J. (2023) · Diagnostics · doi:10.3390/diagnostics13233530 · Cited by 6
Alkaf, B., Abdulrahman, W. M., Marzooqi, S. A., Sanchez, D., Henschel, A., Jha, A. R., Saad, A., Awadhi, A. A., El-Khani, A., Medvedev, A., et al. (2025) · medRxiv · doi:10.1101/2025.10.14.25337784 · Cited by 5
Meng, X., Wong, W., Pushpanathan, K., Srinivasan, S., Xue, C., Wang, M., Miao, H., Li, H., Yang, L., Cen, L., et al. (2025) · Eye · doi:10.1038/s41433-025-04013-8 · Cited by 6
Artificial intelligence applications in inherited retinal dystrophies
Király, P., & Fischer, M. D. (2025) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-025-06956-w · Cited by 4
Haddadzadegan, S., Mehdizdeh, N., Wang, X., Wong, T. T. L., & Miserez, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114841 · Cited by 5
Ng, B., Tan, T., Костин, В. В., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.6.2 · Cited by 4
Moussallem, L., Lombardi, L., McGuinness, M. B., Kolic, M., Baglin, E. K., Jin, R., Habili, N., Kvansakul, J. G. S., Titchener, S. A., Abbott, C. J., et al. (2025) · Journal of Neural Engineering · doi:10.1088/1741-2552/adc83a · Cited by 3
RPGR-Related Retinal Dystrophy in Latin America—A Collaborative Study
Varela, M. D., Moya, R., Luna, J. D., Ciccioli, M., Inga, M. E., Gras, J., Nuova, P. J., Capalbo, L., Antacle, A., Echandi, L. V., et al. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.05.025 · Cited by 2
Hughes, S., Rodgers, J., Lindner, M., Peirson, S. N., Lucas, R. J., & Hankins, M. W. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.056 · Cited by 2
Pechhacker, M. K. G., Molnar, A. E. C., Pacheco, N. P., Thonberg, H., Quérat, L., Birkeldh, U., Nordgren, A., & Lindstrand, A. (2023) · Ophthalmic Genetics · doi:10.1080/13816810.2023.2215332 · Cited by 2
ABCA4 variant screening in a Turkish cohort with Stargardt disease
Kahraman, N. S., Çalışkan, B. Ö., Kandemir, N., Öner, A., Dündar, M., & Özkul, Y. (2024) · Ophthalmic Genetics · doi:10.1080/13816810.2024.2313490 · Cited by 2
Inherited retinal dystrophies and orphan designations in the European Union
Moseley, J., Leest, T., Larsson, K., Magrelli, A., & Stoyanova-Beninska, V. V. (2024) · European Journal of Ophthalmology · doi:10.1177/11206721241236214 · Cited by 2
Leber hereditary optic neuropathy in Slovenia: quality of life and costs from patient perspective
Hawlina, M., Kovač, L., Breciková, K., Zigmond, J., Rogalewicz, V., Tichopád, A., Višňanský, M., & Šarkanová, I. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03329-0 · Cited by 2
Erbliche Netzhauterkrankungen: klinische und molekulargenetische Diagnostik
Kellner, U., & Pfau, K. (2025) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-2274-5801 · Cited by 2
The value of genetic testing in pediatric and adult ophthalmology
Kellner, U., Kellner, S., Weinitz, S., & Farmand, G. (2025) · Medizinische Genetik · doi:10.1515/medgen-2024-2059 · Cited by 3
Marta, A. A., Miranda, V., Lume, M., Parreira, R., Soares, C. A., Menéres, M. J., Lemos, C., & Beirão, J. M. (2023) · Ophthalmology Science · doi:10.1016/j.xops.2023.100443 · Cited by 2
Marques, J. P., Raimundo, M., Paiva, C., Figueira, J., Alfaite, M., da Silva, R. M., & Murta, J. (2021) · Revista Sociedade Portuguesa de Oftalmologia · doi:10.48560/rspo.24654 · Cited by 2
Paudel, N., & Daly, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1481670 · Cited by 1
Self-citationSzpringer-Wabicz, A., Nowomiejska, K., Niedziałek, A., Toborek, M., Wiśniewska, K., Midura, M., Symms, M. R., Ręjdak, R., & Pietura, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165666 · Cited by 1
Patient-Reported Social Impact of Molecularly Confirmed Macular Dystrophies and Cone–Rod Dystrophies
Zehe-Lindau, N., Lindau, B., Stöhr, H., Weber, B. H. F., Spital, G., & Kellner, U. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14227928 · Cited by 1
Zhang, Q., Lum, K., Cai, Q., Wang, W., Wu, T., Besirli, C. G., Clark, M., Song, J., & Sperling, M. (2025) · Ophthalmic Genetics · doi:10.1080/13816810.2025.2591826 · Cited by 1
Gene therapy outcomes in young patients with RPE65-retinal degeneration
STEPHENSON, K., Alsalamah, A. K., Tumber, A. K., Mercer, G., Ballios, B. G., Muni, R. H., Tavares, E. S., Kertes, P. J., Vincent, A., & Héon, E. (2026) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2026.01.016 · Cited by 1
Disparities in Inherited Retinal Degenerations
Chorfi, S., Place, E., & Huckfeldt, R. M. (2022) · Seminars in Ophthalmology · doi:10.1080/08820538.2022.2152715 · Cited by 2
Increased H3K27 trimethylation contributes to cone survival in a mouse model of cone dystrophyPreprint
Miller, A. L., Fuller-Carter, P. I., Masarini, K., Samardzija, M., Carter, K. W., Rashwan, R., Brunet, A. A., Chopra, A., Ram, R., Grimm, C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.07.479069 · Cited by 1
Willmington, C., Kirby, A., & Murphy, A. (2025) · Health Economics Review · doi:10.1186/s13561-025-00707-7
“For instance, while this review identified only one original study estimating costs of IRDs in Europe [59] (reporting direct costs of $900 per patient per annum), other international studies suggested that 81% to 90% of the costs associated with IRDs are indirect and intangible [80–84].”
Genetic counselling and family support
Hall, G., Daly, A., Fasser, C., & Ashworth, J. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-813944-8.00004-4
Self-citationInherited Retinal Dystrophy and Quality of Life Questionnaire: a Scoping Review
de Vasconcellos, C. F. C., Salles, M. V., Sallum, J. M. F., & de Vasconcellos, J. P. C. (2022) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-022-01184-3
Breaking bad news in ophthalmology: a literature review
de Vasconcellos, C. F. C., Pellissari, M. C., Zin, O. A., Salles, M. V., Sallum, J. M. F., & de Vasconcellos, J. P. C. (2022) · Arquivos Brasileiros de Oftalmologia · doi:10.5935/0004-2749.2022-0104
Erbliche Netzhauterkrankungen: klinische und molekulargenetische Diagnostik
Kellner, U., & Pfau, K. (2025) · Augenheilkunde up2date · doi:10.1055/a-2515-3360
Metadata
- Authors
- Galvin, O., Chi, G., Brady, L., Hippert, C., Del Valle Rubido, M., Daly, A., & Michaelides, M.
- Affiliations
- Roche (United States) (US)
- Fighting Blindness (IE)
- F. Hoffmann-La Roche AG (CH)
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- Corresponding author
- Galvin, Orla
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2020-03
- Volume
- Volume 14
- Pages
- 707-719
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- PMC
- PMC7062501
- OpenAlex
- W3009621895
- Cited by
- 116
- References
- 32
- Citations by year
- 2026: 9 · 2025: 27 · 2024: 20 · 2023: 17 · 2022: 24 · 2021: 16 · 2020: 3
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical ophthalmology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Retina UK
- ProQR Therapeutics
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- inherited retinal disease, economic burden, disability-adjusted life years, prevalence, access to genetic testing, genetic counseling, employment discrimination, informal care, health system costs, deadweight loss, value for money, patient and family impact, Ireland, United Kingdom, health policy planning, clinical trial access, patient registry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
